Streetbeat News

Price Targets

NOW

ServiceNow has seen a surge in options trading, with a bearish sentiment prevailing among investors. The stock is currently down 1.69% at $879.31, and experts have set a price target of $900. Recent options trades show a mix of bullish and bearish positions, with a focus on a price range of $760 to $1200.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:16 pm

HUM

Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on Humana (NYSE:HUM) and maintained a price target of $395.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 3:10 pm

HCA

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on HCA Healthcare and maintained a price target of $392.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 3:08 pm

ELV

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $600.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 3:02 pm

VTR

Wells Fargo analyst John Kilichowski has assumed an Overweight rating for Ventas (NYSE:VTR) and raised the price target to $71.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 3:02 pm

CVS

Analysts have provided mixed ratings on CVS Health (NYSE:CVS) over the past three months, with most maintaining a neutral stance. The average 12-month price target is $62.27, with a slight decrease in sentiment. CVS Health's financial metrics show strong profitability and effective asset utilization, but revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

BDX

Analysts have varied opinions on Becton Dickinson (NYSE:BDX), with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $270.0, with a high of $280.00 and a low of $255.00. Analysts have adjusted their ratings and price targets based on market conditions and company performance. Becton Dickinson is a major player in the medical surgical products industry, with strong revenue growth and net margins but challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

CLX

Clorox (NYSE:CLX) has received mixed analyst ratings over the past three months, with a recent average price target of $148.15, slightly down from $149.17. Analysts have adjusted their ratings and price targets, reflecting varied expectations for Clorox's performance. Despite a decline in revenue growth, Clorox maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

FSLY

Analysts have recently adjusted their ratings and price targets for Fastly (NYSE:FSLY), reflecting a more cautious outlook. The average 12-month price target has decreased significantly, indicating a shift in sentiment. Fastly's financial health shows positive revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 3:01 pm

SBRA

Wells Fargo analyst John Kilichowski has assumed coverage of Sabra Health Care REIT with an Overweight rating and increased the price target to $20.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 2:58 pm